Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 39Lymphoma, B-Cell, Marginal Zone 22Lymphoma, Mantle-Cell 19Lymphoma, Follicular 18Lymphoma 17Lymphoma, Non-Hodgkin 15Leukemia, Lymphocytic, Chronic, B-Cell 12Lymphoma, B-Cell 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Recurrence 8Burkitt Lymphoma 8Waldenstrom Macroglobulinemia 7Neoplasms 6Leukemia, Hairy Cell 4Leukemia, B-Cell 3Leukemia 3Hematologic Neoplasms 3beta-Thalassemia 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm, Residual 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Heart Failure 2Epstein-Barr Virus Infections 2Dendritic Cell Sarcoma, Interdigitating 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Anemia, Refractory, with Excess of Blasts 2Thalassemia 1Sjogren's Syndrome 1

Interventions

Specimen Handling 1Rituximab 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Classic Follicular Lymphoma × Rituximab × Clear all
NCT06337318 2026-05-29

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

National Cancer Institute (NCI)

Phase 3 Recruiting
600 enrolled
Lymphoid

Classic Follicular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡